Medical Food for the Dietary Management of Metastatic Colorectal Cancer
This is a single arm study evaluating the tolerability and markers of colorectal cancer with a specially designed medical food restricted in specific amino acids for the dietary management of subjects with metastatic colorectal cancer. Subjects will be receiving two FDA approved second line drug therapies, fluoropyrimidine and oxaliplatin ± bevacizumab (FOLFIRI + BEV) that are routinely prescribed in combination for metastatic colorectal cancer as part of their routine care.
Metastatic Colorectal Cancer
OTHER: NEAAR Medical Food
Tolerability of the NEAAR medical food, Rate of the most common Grade 3 and 4 adverse event (AE) related to the NEAAR medical food., Through study completion (average of 6 months)
Overall response rates, Complete response and partial response per RECIST 1.1, Through study completion (average of 6 months)|Changes in biomarkers, Absolute and relative change from baseline for disease biomarkers, Through study completion (average of 6 months)|Progression-free Survival, Duration from radiographic documentation of disease to radiographic documentation of progression or death from any cause, 6, 9 and 12 months
This is a single arm study evaluating the tolerability and markers of colorectal cancer with a specially designed medical food restricted in specific amino acids for the dietary management of subjects with metastatic colorectal cancer. Subjects will be receiving two FDA approved second line drug therapies, fluoropyrimidine and oxaliplatin ± bevacizumab (FOLFIRI + BEV) that are routinely prescribed in combination for metastatic colorectal cancer as part of their routine care.